Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a novel vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.

中文翻译：

---

基于合成痘病毒的 SARS-CoV-2 疫苗的开发。

改良的安卡拉痘苗 (MVA) 是一种高度减毒的痘病毒载体，广泛用于开发传染病和癌症疫苗。我们开发了一种基于独特的三质粒系统的新型疫苗平台，可以从化学合成的 DNA 中有效地生成重组 MVA 载体。为了应对由 SARS 冠状病毒-2 (SARS-CoV-2) 引起的持续全球大流行，我们使用这种新型疫苗平台快速生产全合成 MVA (sMVA) 载体，共表达 SARS-CoV-2 尖峰和核衣壳抗原，两种免疫显性抗原与保护性免疫有关。用这些 sMVA 载体免疫的小鼠产生了强大的 SARS-CoV-2 抗原特异性体液和细胞免疫反应，包括有效的中和抗体。